# A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

> **NCT05310071** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 1027 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05310071
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-02
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 1027 (ACTUAL)
- **Why stopped:** Sponsor's Decision
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310071, "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05310071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*